Quarterly ResultMay 7, 2026, 07:08 AM
NewAmsterdam Pharma Q1 Net Loss $48.4M; PREVAIL Interim Analysis 4Q26
AI Summary
NewAmsterdam Pharma reported a net loss of $48.4 million for Q1 2026, an increase from $39.5 million in Q1 2025, while revenue remained flat at $3.0 million. The company maintained a strong cash position of $707.3 million as of March 31, 2026. Significant clinical progress includes an interim analysis for the PREVAIL Phase 3 trial planned for Q4 2026, with results expected in Q1 2027, and topline data from the RUBENS Phase 3 trial anticipated by year-end 2026. Regulatory approval decisions for obicetrapib in Europe are expected in the second half of 2026.
Key Highlights
- PREVAIL Phase 3 interim analysis planned for Q4 2026, with results expected in Q1 2027.
- Topline data from RUBENS Phase 3 trial expected by year-end 2026.
- Cash, cash equivalents, and marketable securities totaled $707.3 million as of March 31, 2026.
- Q1 2026 revenue was $3.0 million, consistent with Q1 2025.
- Q1 2026 net loss increased to $48.4 million from $39.5 million in Q1 2025.
- R&D expenses decreased to $38.0 million in Q1 2026 from $44.8 million in Q1 2025.
- SG&A expenses decreased to $23.5 million in Q1 2026 from $27.2 million in Q1 2025.
- Regulatory approval decisions for obicetrapib in Europe expected in 2H 2026.
Price Impact
More from NAMS